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Abstract
Background: Accurate and high-throughput genotyping of Mycobacterium tuberculosis complex (MTBC) may be
important for understanding the epidemiology and pathogenesis of tuberculosis (TB). In this study, we report the
development of a LightCycler® real-time PCR single-nucleotide-polymorphism (LRPS) assay for the rapid
determination of MTBC lineages/sublineages in minimally processed sputum samples from TB patients.
Method: Genotyping analysis of 70 MTBC strains was performed using the Long Sequence Polymorphism-PCR
(LSP-PCR) technique and the LRPS assay in parallel. For targeted sequencing, 9 MTBC isolates (three isolates per
MTBC lineage) were analyzed for lineage-specific single nucleotide polymorphisms (SNPs) in the following three
genes to verify LRPS results: Rv004c for MTB Uganda family, Rv2962 for MTB lineage 4, and Rv0129c for MTB lineage
3. The MTBC lineages present in 300 smear-positive sputum samples were then determined by the validated LRPS
method without prior culturing.
Results: The LSP-PCR and LRPS assays produced consistent genotyping data for all 70 MTBC strains; however, the
LSP-PCR assay was 10-fold less sensitive than the LRPS method and required higher DNA concentrations to
successfully characterize the MTBC lineage of certain samples. Targeted sequencing of genes containing lineage-
specific SNPs was 100 % concordant with the genotyping results and provided further validation of the LRPS assay.
Of the 300 sputum samples analyzed, 58 % contained MTBC from the MTBC-Uganda family, 27 % from the MTBC
lineage 4 (excluding MTBC Uganda family), 13 % from the MTBC lineage 3, and the remaining 2 % were of
indeterminate lineage.
Conclusion: The LRPS assay is a sensitive, high-throughput technique with potential application to routine
genotyping of MTBC in sputum samples from TB patients.
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Introduction
Mycobacterium tuberculosis (MTB) is an acid-fast bacil-
lus that causes tuberculosis (TB) a chronically debilitat-
ing disease with a mortality rate approaching 2 million
deaths per year [1–3]. The disease primarily develops in
5–10 % individuals following inhalation of air droplets
containing Mycobacterium tuberculosis complex (MTBC)
bacilli, but may also occur following reactivation of a la-
tent infection [4]. In Kampala, Uganda, 3 dominant
MTBC genotypes have been identified namely MTBC
Uganda family that accounts for 63 % of TB cases,
followed by other MTBC lineage 4 genotypes other than
Uganda genotype and then MTBC lineage 3 [5, 6]. These
genotypes present with diverse clinical outcomes for in-
stance MTBC Uganda family genotypes are less prone to
drug-resistance, less virulent, and not associated with
extra pulmonary TB [5, 7–10]. The MTBC lineage 4
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genotypes progress rapid to disease compared to other
genotypes [11, 12], while the MTBC lineage 3 genotypes
cause severe disease [13]. Therefore accurate determin-
ation of the MTBC strain diversity within a population
like Kampala can lead to the design of intervention strat-
egies that more effectively target circulating strains.
The currently available MTBC genotyping assays are
challenging to implement in areas with endemic TB and
are limited in their ability to discriminate MTBC strains
present in clinical isolates. For example robust tech-
niques such multi-locus sequence typing (MLST) [14]
and whole genome sequencing (WGS) [15, 16], are diffi-
cult to adopt in resource-limited countries because they
are prohibitively expensive [17]. Other techniques, such
as MIRU-VNTR, IS6110-RFLP, PGRS-RFLP, and CRISP
[18, 19], can erroneously classify MTBC lineages [16, 20]
due to homoplasy and are technically cumbersome. Fur-
thermore, some of these methods typically require prior
culturing of MTB from sputum samples, a process that
takes 1–2 months [21]. For samples containing a mixed
MTBC population, this culturing step may skew strain
diversity by promoting growth competition between dif-
ferent strains [22]. Thus, there is a need for a more ro-
bust genotyping assay that is fast, sensitive, and can be
applied directly to processed sputum samples without
prior culturing.
To mitigate the aforementioned flaws a real-time PCR
(RT-PCR) assay—the LightCycler® 480 RT-PCR SNP
(LRPS) assay—was developed to genotype MTBC directly
from processed sputum samples using hybridization
probes. This assay was evaluated for the ability to accur-
ately identify MTBC lineages in peri-urban Kampala and
subsequently used to analyze 300 smear-positive sputum
samples from individual patients.
Materials and methods
Identification of lineage-specific SNPs for genotyping
MTBC
The MTBC lineage-specific SNPs used in this study
were obtained from whole genome sequencing data as
previously described [14 16] with reference to the first
MTBC (i.e., H37Rv) genome [23] to be sequenced. A
SNP corresponding to a specific MTB lineage/sublineage
was annotated by showing its position in the corre-
sponding gene (ORF) and the associated nucleotide
change (See Additional file 1: Table S1).
Design of primers and probes for LRPS assay
Primers and probes for typing MTBC Uganda family (MTB
L4-U) MTBC lineage 4 excluding the MTBC Uganda fam-
ily (MTB L4-NU), and MTBC lineage 3 (MTB L3) were
chosen based on the list of lineage-specific SNPs described
previously [14, 16] (See Additional file 2: Table S2). Light-
Cycler® Probe Design Software 2 (Roche Applied Science,
Germany) was used for the design of assay primers and
probes. In brief, RT-PCR enables the quantitative detection
of a particular segment of DNA by coupling a fluorescent
signal with DNA amplification. The fluorescence produced
during amplification is directly proportional to the amount
of DNA present in a given sample, amplification efficiency
of the primer and probe combination. In order to distin-
guish the DNA of different MTBC lineages, hybridization
probes were designed to recognize unique SNPs that are
specific to particular MTBC lineages/sublineages. To iden-
tify MTBC L4-U and MTBC L3, hybridization probes were
designed to perfectly complement wild type (H37Rv) DNA
for MTBC L4-NU probes were designed to complement
the mutant DNA. Thus, for MTBC L4-U and MTBC L3
probes will produce lower melting temperature (Tm) values
(due to single base mismatch) than samples with wild type
DNA (due to perfect match), whereas the MTBC L4-NU
probes will produce higher Tm values with mutant DNA
(due to perfect match). We used MTBC lineage 3 (CAS),
Uganda family and H37Rv DNA as controls.
MTBC DNA extraction
The genomic DNA from stored isolates was extracted as
described by Wampande et al. Stucki et al. [5, 24]. Fro-
zen isolates that were earlier characterized as MTBC by
IS6110-PCR were thawed, centrifuged, and the pellet
washed twice with phosphate buffer saline (PBS). Pellets
were subsequently reconstituted in 100 μl PCR water,
heated at 90 °C for 1 h, and sonicated for 15 min to
completely lyse the bacilli and release the genomic
DNA. The latter was recovered in the supernatant fol-
lowing centrifugation at 13000 g for 30 min, quantified
by Qubit® 2.0 fluorometer (Invitrogen, USA) and used
immediately or stored at −20 °C for future use.
Long sequence polymorphism (LSP) -PCR analysis
In order to ascertain whether the LRPS assay correctly
identifies MTBC lineage we compared the LRPS results
with LSP-PCR data using genomic DNA extracted from
70 MTBC stored isolates. LSP-PCR was performed using
RD 724 deletion primers (specific for MTB Uganda fam-
ily) and RD750 deletion primers (Specific for MTB
lineage 3) as described by Gagneux et al. [25] and Tso-
laki et al. [26]. The 10 μl reaction volume PCR was con-
taining 5.5 μl water, 1 μl (10 μM final concentration)
forward primer (RD 724 or RD 750) and 1 μl (10 μM
final concentration) reverse primer (Reverse RD 724 or
RD 750), 1 μl of 10 x Thermo Fischer Scientific Custom
PCR Master mix, 1 μl template DNA (at least 50 ng)
and 0.5 μl (0.5 unit) DNA polymerase. The reaction was
run in a standard thermocycler programmed at 95 °C for
10 min 35 cycles of 95 °C for 1 min, 64 °C for 30 s and
72 °C for 30 s. PCR products were analyzed by gel
electrophoresis.
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PCR and targeted sequencing
To further validate the LRPS assay target sequencing of
three ORFs (Rv004c for MTBC L4-U Rv2962 for MTBC
L4 and Rv0129c for MTBC L3) which contain lineage-
specific SNPs from 9 MTBC isolates was performed
using primers in Table 1. The PCR was run in a 20 μl re-
action volume with 12 μl water 1 μl forward primer and
1 μl reverse primer (0.5 μM of each of the primers), 4 μl
of 5 x Roche genotyping master mix (containing Taq
polymerase and dNTPs), and 2 μl template DNA (at
least 50 ng). The reaction was run in a standard thermo-
cycler (95 °C for 10 min 35 cycles of 95 °C for 10 s
primer(s) annealing (57 °C for Rv004c ORF or 53 °C for
Rv0129c ORF or 51 °C for Rv2962 ORF) for 10 s 72 °C
for 10 s. PCR products were analyzed by gel electrophor-
esis purified by Qiagen PCR purification kit and com-
mercially sequenced using the primers designed for the
specific ORFs (See Table 1). To confirm the presence of
the SNP in the respective ORFs, BioEdit software (Ibis
Biosciences, USA) was used to align the corresponding
H37Rv ORF with the sequenced fragments.
Patient recruitment and processing sputum samples
Patients were recruited from Mulago hospital TB clinic
(ward 5 & 6) which serves as the main referral TB centre
in Uganda. Sample processing confirmatory microscopy
(both ZN and auramine staining) and culturing was
done at Mycobacteriology Laboratory, Department of
Medical Microbiology, College of Health Sciences,
Makerere University. 300 sputum samples were proc-
essed in a Biosafety cabinet class II following standard
procedures [27]. The final sediment was suspended in
2.5 ml PBS buffer (pH 6.8) part of this sample was used
to inoculate Middlebrook 7H10 supplemented with 10 %
(v/v) glycerol and OADC for culturing following stand-
ard procedures [28] and the remainder was re-
suspended in 50 μl of PCR water for DNA extraction.
The latter was heat killed at 95 °C for 1 h and later soni-
cated for 15 min to completely lyse the bacilli and re-
lease the genomic DNA. The genomic DNA was
obtained in the supernatant following centrifugation at
13000 rpm and stored at −20 °C or used immediately in
the LRPS assay.
LRPS genotyping assay
Genotyping of MTBC from cultured and frozen isolates
or processed sputum samples was performed using
ORF-specific primers and probes designed based on
SNP positions (See Table 1 and Additional file 2: Table
S2) in Roche LightCycler ® RT-PCR 480 machine (Roche
Applied Science Germany). Briefly, the LRPS assay was
run in 20 μl reaction containing 11.2 μl of PCR water,
1 μl (0.5 μM final concentration) reverse primer, 1 μl
(0.5 μM final concentration) of forward primer, 0.4 μl
(0.4 μM final concentration) of the donor probe, 0.4 μl
(0.4 μM final concentration) of the acceptor probe, 4 μl
of 5 x Roche genotyping master mix, and 2 μl (contain-
ing at least 5–50 ng) of extracted genomic DNA. The
Roche LightCycler® 480 (Roche Applied Science,
Germany) was programmed for PCR amplification and a
melting curve stage. For each of the three uniplex assays,
the amplification stage consisted of a pre-PCR stage per-
formed at 95 °C for 10 min, an amplification stage with
denaturation at 95 °C for 10 s, primer annealing (57 °C
for Rv004c ORF or 53 °C for Rv0129c ORF or 51 °C for
Rv2962 ORF) for 10 s with a single acquisition mode to
allow capture of the fluorescence, and extension at 72 °C
for 10 s for 45 cycles. The melting curve analysis
Table 1 SNPs markers, primers and probes used in RT-PCR
SNP Name Primer and probes Tm-1 Tm-2 Primer annealing
temperature
Fragment
length (bp)
Rv004c-0619n (MTB L4-U) Forward:5-ATT GCT CGA TGG CAG A-3 a62 °C 68 °C 57 °C 160
Reverse: 5-AAA CCA GGT ACT TGT CGG-3
LC Red 640-TGA TGA CGG AAA GCC GT GAA A-Pho-3
5-GTT TTC GCG GTA GGT GCC CTC GAT G-Fluo-3
Rv2962c-0711 s (MTB L4-NU) Forward: 5-GAA CGC CCT TTG CTC TTC-3 56 °C a64 °C 51 °C 181
Reverse:5-CAA GGT ACT CGT GGT TGG-3
LC Red 610- CCC GAG CTG ATG CCC ACC T-Pho-3
5-CAC ACC CTG TAT GC GAC G-Fluo-3
Rv0129c-0472n (MTB L3) Forward:5-CGA CTG GTA TCA GCC CTC-3 a58 °C 68 °C 53 ° C 191
Reverse:5-GGA ACT GCT GCG GGT AGT A-3
LC Red 610-GAC ACG C C TTG TTG GCC-Pho-3
5-CGC CGC GTT GCC TGT CG –Fluo-3
Shaded and bold nucleotide denotes SNP position relative to H37Rv MTB genotype
aDenotes MTB lineage specific melting temperature (Tm)
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consisted of denaturation of amplicons at 95 °C for
1 min to produce single stranded DNA (ssDNA), probe
annealing temperature at 40 °C (allows hybridization of
the probes to the complimentary sites of the ssDNA) for
10 s, probe melting temperature ranging from 40–80 °C
(allows the probe to detach from the ssDNA) with a
continuous mode of acquisition at a rate of 1 acquisi-
tion/s that allows capture of the fluorescence.
Data analysis
From the melting curves the LightCycler® 480 software
version 1.2 (Roche Applied Science, Germany) was used
to derive probe melting temperature (Tm), which is
lineage-specific. For MTBC Uganda family and MTB
Lineage 3, the Tm was lower (due to mismatch) than the
wild type (perfect match) yet for MTBC lineage 4 the
Tm (due to perfect match) was higher than the wild
type.
Ethical consideration
This study obtained ethical approval from Makerere
University institutional review board and the Uganda
National Council for Science and Technology. Written
informed consent was obtained from all the study
participants.
Results
Primers and probes used in genotyping MTBC
A total of eight primer/probe sets were successfully de-
signed using the LightCycler® probe design (Roche Ap-
plied Science Germany) software 2 (Additional file 2:
Table S2). During the LRPS optimization step primer
probe set Rv0006a and Rv0407b failed to give signals (no
amplification), primer/probe set Rv3133cC and Rv2959c
were giving results that were conflicting with the posi-
tive (Central Asian Strain, CAS) and negative controls
(H37Rv), thus these sets were excluded. Also Primer/
probe set Rv2949ca was excluded from further sample
analysis since it required twice the probe concentration
as the counterpart. Therefore primer/probe sets Rv004ca
was used to analyze samples for presence of MTBC
Uganda family; Rv2962b and Rv0129cc primer sets were
used to identify MTBC lineage 4 and MTBC lineage 3
respectively (Table 1).
Identification of MTBC Uganda family using LSP-PCR and
LRPS assay
LSP-PCR and targeted sequencing reactions were run in
parallel to validate the LRPS assay. A total of 70 MTBC
isolates (confirmed by IS6110 PCR) were genotyped
using LSP-PCR with primers specific for the RD 724 de-
letion in parallel with LRPS assay using Rv004ca primer/
probes set (Table 1). While both assays were equally cap-
able of identifying MTBC Uganda (Fig. 1 and Additional
file 5 Fig S2(a)) only the LRPS assay was able to geno-
type all 70 samples the LSP-PCR assay failed to identify
the MTBC lineages of several isolates (Fig. 1: lane 11 13,
14, 15, 21, 22, 26, 27, 33, 39, 43, 45, 56, 61, 62). With
that result, both assays were re-evaluated using serially
diluted H37Rv genomic DNA (10 ng–100 ng for LSP-
PCR and 1 ng–10 ng for LRPS per PCR reaction) ex-
tracted by the Enzyme/CTAB method [29]. The detec-
tion limit of the LSP-PCR assay was 10-fold higher than
that of the LRPS assay (30 ng approximately 7 × 106 cop-
ies/reaction and 3 ng approximately 7 × 105 copies/reac-
tion) respectively (Additional file 4: Figure S1). Later,
DNA from those samples that previously produced no
LSP-PCR product (Fig. 1: lane 11,13,14,15, 21, 22, 26, 27,
33, 39, 43, 45, 56, 61, 62) were re-extracted and repeated
the LSP-PCR genotyping reactions with at least 30 ng
template DNA. This time, genotyping data were ob-
tained for all isolates and were in agreement with those
of the LRPS assay (data not shown).
Identification of MTBC Lineage 3 genotype using LSP-PCR
and LRPS
A total of 33 MTBC isolates (See Additional file 3: Table
S3) that were not MTBC Uganda (non-Uganda family
MTBC) by RD 724 analysis (See Fig. 1 lane 4 5, 6, 17,
19, 20, 23, 24, 25, 35, 36, 37, 38, 41, 47, 57, 65, 66, 67,
68, 69 plus 12 isolates that were initially negative by
RD724 analysis) were further genotyped by LSP-PCR
(RD 750 deletion) and LRPS using MTBC L3-specific
probes (Rv0129cc primer/probe set). Both assays were
100 % concordant in identifying MTBC lineages 3
(Fig. 2a lane 5 9, 16, 28, 29, 31, 32, 33, 34, 35, Fig. 2b
peak with 57 °C and Additional file 5 Fig S2b).
Sequencing PCR products to identify MTB lineage-specific
SNP
To ascertain the accuracy of LRPS in genotyping MTBC
lineages PCR products of 9 MTBC isolates (3 isolates for
each lineage) were sequenced. The resulting sequences
of the gene containing the lineage-specific SNP were
compared with the corresponding H37Rv sequences
using Bio Edit software (Ibis Biosciences, USA) the data
confirmed that the sequenced PCR products contained
lineage-specific SNPs (See Fig. 3).
LRPS typing directly from processed sputum samples
A total of 300 freshly processed sputum samples were
analyzed using LRPS (with primer/probe set Rv004a for
MTBC L4 U Rv2962b for MTBC L4-NU and Rv0129cc
for MTBC L3). Of those 58 % (174/300) were MTBC
L4-U, 27 % (82/300) MTBC L4-NU, 13 % MTBC L3
(39/300) and 2 % (5/300) could not be classified (See
Fig. 4b) 4 % (11/300) had more than one genotype
(double peaks in green) of MTBC. Efforts to confirm the
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presence of more than one genotype (for samples with
double peaks) in the sputum sample by 15 MIRU-VNTR
were futile since none of the alleles was amplifiable.
These data corroborated well with the matched sputum
samples that were cultured and later genotyped with
LRPS except for samples that had more than one geno-
type (i.e. only one genotype was identified). For LRPS
approximately 2 h are required to analyze 92 samples
[the LightCycler® RT-PCR 480 machine uses 96 multi
well sample plates) from the time of sample preparation
to genotype identification.
Discussion
A number of useful SNPs for robust genotyping of
MTBC have been made available following the interro-
gation of whole genome sequence (WGS) data from glo-
bal MTBC strains [14, 16, 30, 31]. Comparisons of SNPs
with other markers used in molecular epidemiological
studies of MTBC have proved their superiority since
they are able to discriminate closely unrelated (no
homoplasy) genotypes of MTBC [16]. Therefore, this
study evaluated the use of novel single nucleotide poly-
morphic (SNP) markers in a LightCycler ® 480 (Roche,
Germany) real-time PCR (LRPS) assay to genotype
MTBC isolates using heat inactivated samples. First,
SNP-pecific primers/probes were designed to accurately
delineate MTBC lineages by real time PCR (RT-PCR).
Secondly, the optimized and validated LRPS was used to
sub-type MTBC lineages present in 300 smear-positive
sputum samples from different individuals. By and large,
these data suggest that LRPS can be used to accurately
identify MTBC genotypes using heat killed crude lysates
of processed sputum samples without prior culturing.
The findings show the successful use of 3 sets of
primers/hybridization probes containing MTBC lineage-
specific SNPs in RT-PCR (LRSP) to accurately delineate
MTBC lineages (MTBC L4-U MTBC L4-NU and MTBC
L3). The LRSP assay is based on coupling a fluorescent
dye to an amplified segment of DNA and use of MTBC
lineage specific probes-conjugated to dyes that ensures
Fig. 1 Comparing RD 724 LSP-PCR and LRPS typing: Samples (N = 70) were analyzed by primers specific for RD 724 (lane M =DNA marker, 1 =MTB
Uganda genotype, 2 = H37Rv, 3 = negative control (no DNA added), lane 4–72 = test samples) a band of 1.5 kb identifies MTB Uganda family, while
that of 1.3 kb identifies other MTBC other than Uganda family (Panel a). For Panel b specific primers/probes (Rv004c primer/probe set) containing
lineage specific SNP were used, the top panel shows the amplification (see also Additional file 5: Figure S2a) of the target region while the bottom
panel shows the derived melting temperature. A peak of 62 °C shows the Uganda family while that of 68 °C shows the wild type (non-Uganda family)
Wampande et al. BMC Infectious Diseases  (2015) 15:396 Page 5 of 10
real-time identification of the genotype in 2 h for every
92 samples. This is contrary to other MTBC genotyping
assays that require different step(s) for detection of the
genotype, hence increasing the turnaround time 1–3
days depending on the method [17]. Comparison of
LSP-PCR and targeted sequencing data of genes contain-
ing these lineage-specific SNPs as a step to validate the
SNP assay indicate 100 % concordance. This agreement
was not surprising since LSP-PCR, LRPS and sequencing
methodologies have been used before to accurately
genotype MTBC [14, 16, 32]. However, the detection
limit of LSP-PCR was 10-fold higher than the SNP-
based assay, thus rendering LRPS more sensitive (3 ng/
assay or 7 × 105 copies/reaction) enough to be used with
low DNA concentration as well as with heat-inactivated
samples. The advantage of using heat lysates eliminates
the long steps in DNA extraction which is labor inten-
sive and time consuming. Thus, the LRPS may be better
suited for genotyping MTBC from processed sputum
samples, which can have a low bacillary load. The
enhanced ability to detect small amounts of DNA in a
sample by LRPS can likely be attributed to the more sen-
sitive fluorescence detection system of the Roche Light-
Cycler® 480 (Roche Applied Science, Germany) machine
[33]. In contrast, conventional PCR-based assays are lim-
ited by quantifiable DNA, the relatively poor sensitivity
of gel-based DNA detection systems, and have a long
turnaround time [34]. To support this observation, PCR-
based genotyping methods such as spoligotyping and
MIRU-VNTR require 20–50 ng of template DNA for a
successful run if the detection system is modified as seen
in luminex spoligotyping (Luminex Technology, TX,
USA) or automated MIRU-VNTR, the sensitivity in-
creases and the turnaround time is reduced, but these
methods are still prone to misclassification of MTB line-
ages [17]. Taken together, this data suggest that the LRPS
is more sensitive than the LSP-PCR approach and fast in
identifying MTBC in clinical samples since the culturing
step is eliminated, making it more suitable for early TB
diagnosis, genotyping applications that involve samples
Fig. 2 Comparing RD 750 LSP-PCR and LRPS typing: Samples (N = 33) were analyzed by primers specific for RD 750 (lane M =DNA marker, 1 = H37Rv,
2 = negative control (no DNA added), lane 3–36 = test samples), a band of 0.75 kb identifies MTB Lineage 3, while that of 1.3 kb identifies other MTBC
other than MTB Lineage 3 (See Panel a). For Panel b specific primers and probes (Rv0129cc primer/probe set) containing Lineage-3 specific SNP were
used, the top panel shows the amplification (see also Additional file 5: Figure S2) of the target region while the bottom panel shows the derived
melting temperature. A peak of 57 °C shows MTB lineage 3 while that of 67 °C shows the wild type (non-lineage 3)
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with low bacillary loads for instance in TB/ HIV co-
infected patients and smear negative TB patients.
Unlike the LRPS most available genotyping methods
rely on prior culturing of MTBC, which is labor-
intensive, time-consuming, and introduces the risk of se-
lective growth in cases of mixed infections [35]. While
previous efforts have been made to sub-type MTBC iso-
lates directly from sputum using MTB lineage-specific
PCR, MIRU-VNTR and spoligotyping, these approaches
have seen limited success [35, 36] due to their require-
ment for relatively high amounts of DNA and/or the
presence of inhibitors in the sample and a long turn-
around time. In the current study, validated novel SNP-
based genetic markers were evaluated to genotype
MTBC isolates directly from processed sputum by LRPS
without prior culturing. The assay successfully geno-
typed 300 MTBC isolates from sputum samples of these
58 % were classified as MTB L4-U, 27 % as MTB L4-
NU, 13 % as MTB L3 and 2 % as unknown MTBC
lineage, and these proportions did not significantly differ
from the work published by Wampande et al., 2013 [6].
Notably, the LRPS assay was able to detect more than
one genotype in certain isolates (11/300) in contrast the
MIRU-VNTR method failed to reveal mixed infections
in these samples, presumably due to the lack of suffi-
cient DNA. Overall, these data indicate that the LRPS
assay can be used directly on smear-positive, processed
sputum samples to genotype MTBC. Due to its high
sensitivity and the use of 2 probes with distinct melting
curves, this assay has the potential to detect mixed in-
fections in clinical isolates.
Limitations
While the probes used in this study were designed to
rapidly identify the three MTBC lineages circulating in
peri-urban Kampala [5] additional MTBC lineage-
specific probes would need to be developed to genotype
other MTBC lineages/sublineages. The current assay is
robust in defining deep phylogeny, but is alone not suit-
able for transmission studies in such circumstances
MIRU-NVTR could be used in tandem with the LRPS
assay. PCR inhibition was not observed in the LRPS
assay, but, it could be relevant and impact negatively on
the assay due to minimal buffering. Furthermore, only
Fig. 3 Pair wise alignment of H37Rv (wild type) and MTB lineage (mutant) sequences: BioEdit Version 7.2.5 (Ibis Biosciences, USA)was used to
align the wild type (Rv004c, Rv2962 and Rv0129c) and the corresponding mutant (MTB L3, MTB L4-NU or MTB L4-U) sequences. The shaded and
bold nucleotide shows the point mutation
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smear-positive sputum samples, which typically contain
a high MTB DNA concentration were analyzed in this
study thus further studies will be required to evaluate
assay performance on smear-negative samples. The
maintenance and initial cost of Roche LightCycler® 480
(Roche Applied Science, Germany) machines are very
high, however LRPS is robust, of high throughput, and
fast to perform: it has diverse applications, for instance,
mRNA display studies, HIV viral load studies and as an
ordinary PCR machine.
Conclusion
The LRPS assay is a sensitive rapid, simple and high-
throughput technique for detecting and/or genotyping
MTBC from minimally processed, smear positive sputum
and should be broadly applicable to genotyping SNPs in
other microorganisms.
Additional files
Additional file 1: Table S1. Lineage-specific SNPs for MTB Uganda
family, MTB lineage 4 and MTB lineage 3. (DOCX 20 kb)
Additional file 2: Table S2. Primer/probe used in genotyping MTB.
(DOCX 21 kb)
Additional file 3: Table S3. LSP-PCR and LRPS sample analyses.
(DOC 43 kb)
Additional file 4: Figure S1. LRPS is more sensitive than LSP-PCR
typing: H37Rv genomic DNA was serially diluted and analyzed with RD
724 (N = 10) or RD 750 (N = 10) deletion primers: lane M =molecular
weight markers, lane 1 positive control (MTB Uganda family or lineage 3
strain), lane 2 negative control, lane 3- 12 H37Rv DNA diluted from 100-
10 ng; the minimum dilution of genomic DNA that can be amplified was
Fig. 4 Analysis of smear positive sputum samples: LRPS identified MTB lineages/sublineages in the sputum samples (N = 300). Panel a shows the
derived melting curves showing single genotypes (Red; single peaks) and double genotypes (Green; double peaks). Panel b shows the overall
proportion of MTBC lineages from the total number of samples analyzed
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in lane 10 (30ng) (Plate a & c). Plate b & d are the corresponding LRPS
using Rv004c/probe or Rv0129c/probe set with H37Rv genomic DNA
diluted from (10-1) ng per assay, the minimum dilution of DNA that
can be amplified was 3ng (See arrow on the amplification curves plate
b & d). (DOC 179 kb)
Additional file 5: Figure S2. Fluorescence applification curve readings:
Specific Rv004c and Rv0129c primer/probe set containing lineage specific
SNP were used to analyze 70 and 33 MTBC isolates respectively.
Amplification fluorescence curves for Rv004c and Rv0129 target region
are shown in panel (a) and panel (b) respectively. (DOC 123 kb)
Abbreviation
MTBC: Mycobacterium tuberculosis complex; TB: Tuberculosis; Tm: Melting
temperature; SNP: ingle nucleotide polymorphism; RT-PCR: Real time
polymerase chain reaction; LSP-PCR: Long sequence polymorphism-
Polymerase chain reactiom; MLST: Multilocus sequence typing;
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